These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 28799578)

  • 1. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possible treatments for infantile spinal atrophy].
    Pascual-Pascual SI; Garcia-Romero M
    Rev Neurol; 2017 May; 64(s03):S19-S24. PubMed ID: 28524214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
    Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy.
    Maharshi V; Hasan S
    Clin Drug Investig; 2017 Sep; 37(9):807-817. PubMed ID: 28755059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW; Yokota T
    Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.
    Glascock J; Sampson J; Haidet-Phillips A; Connolly A; Darras B; Day J; Finkel R; Howell RR; Klinger K; Kuntz N; Prior T; Shieh PB; Crawford TO; Kerr D; Jarecki J
    J Neuromuscul Dis; 2018; 5(2):145-158. PubMed ID: 29614695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.